110 related articles for article (PubMed ID: 8780746)
1. Therapy-related leukemia with a novel 21q22 rearrangement.
Izumi T; Ohtsuki T; Ohya K; Ogawa Y; Yoshida M; Muroi K; Imagawa S; Hatake K; Kuriki K; Saito K; Miura Y
Cancer Genet Cytogenet; 1996 Aug; 90(1):45-8. PubMed ID: 8780746
[TBL] [Abstract][Full Text] [Related]
2. A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.
Takeda K; Shinohara K; Kameda N; Ariyoshi K
Int J Hematol; 1998 Feb; 67(2):179-86. PubMed ID: 9631585
[TBL] [Abstract][Full Text] [Related]
3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
5. Translocation (1;11)(q23;p15), a novel simple variant of translocation (7;11)(p15;p15), in a patient with AML (M2) accompanied by non-Hodgkin lymphoma and gastric cancer.
Hatano Y; Miura I; Kume M; Miura AB
Cancer Genet Cytogenet; 2000 Feb; 117(1):19-23. PubMed ID: 10700860
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of elderly patients with non-Hodgkin's lymphoma].
Titorenko IB; Kriachok IA
Lik Sprava; 2011; (5-6):79-85. PubMed ID: 22606896
[TBL] [Abstract][Full Text] [Related]
7. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
[No Abstract] [Full Text] [Related]
8. Morphological and cytogenetic changes in therapy-related leukemia developed in a t(8;21)-acute myeloid leukemia (M2) patient: sequential cytogenetic and molecular analyses.
Nawata R; Shinohara K; Yamada T; Takahashi T; Katsuki K; Takeda K; Kameda N; Ariyoshi K; Ota I; Muraki K
Int J Hematol; 2000 Jun; 71(4):353-8. PubMed ID: 10905055
[TBL] [Abstract][Full Text] [Related]
9. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
10. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
11. Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Wang H; Yang W; Shao H; Zhang J; Qi L; Liao A; Li Y; Liu Z
Cancer Genet Cytogenet; 2009 Jan; 188(2):95-8. PubMed ID: 19100512
[TBL] [Abstract][Full Text] [Related]
12. A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.
Kondoh K; Nakata Y; Furuta T; Hosoda F; Gamou T; Kurosawa Y; Kinoshita A; Ohki M; Tomita Y; Mori T
Leuk Lymphoma; 2002 Feb; 43(2):415-20. PubMed ID: 11999578
[TBL] [Abstract][Full Text] [Related]
13. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
Lichtman SM; Brody J; Kaplan MH; Susin M; Koduru P; Goh JC
Leuk Lymphoma; 1993 Mar; 9(4-5):393-8. PubMed ID: 7688628
[TBL] [Abstract][Full Text] [Related]
15. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
16. ABEP as primary chemotherapy for Hodgkin's disease.
Zulian GB; Mermillod B; Alberto P
Eur J Cancer; 1992; 28A(10):1727-9. PubMed ID: 1382495
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related, mixed phenotype acute leukemia with t(1;21)(p36;q22) and RUNX1 rearrangement.
Yamamoto K; Sada A; Kawano Y; Katayama Y; Shimoyama M; Matsui T
Cancer Genet Cytogenet; 2010 Sep; 201(2):122-7. PubMed ID: 20682397
[TBL] [Abstract][Full Text] [Related]
18. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
19. A case of acute myeloblastic leukemia with a novel variant of t(8;21)(q22;q22).
Kawakami K; Nishii K; Hyou R; Watanabe Y; Nakao M; Mitani H; Murata T; Monma F; Yamamori S; Hosokai N; Miura I
Int J Hematol; 2008 Jan; 87(1):78-82. PubMed ID: 18224418
[TBL] [Abstract][Full Text] [Related]
20. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
